{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:12:45Z","timestamp":1791313965227,"version":"4.3.1"},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2020,4,17]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Aripiprazole, a synthetic compound, obtained by chemical modification of the structure of quinolinone is considered as an atypical antipsychotic drug. The present review is an attempt to summarize the updated information related to reported chemistry and pharmacology of Aripiprazole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Development:<\/jats:title>\n                    <jats:p>Aripiprazole, under development by Otsuka Pharmaceutical, was approved by the U.S. Food and Drug Administration (USFDA) by the end of 2002 with an aim to treat patients with schizophrenia. This drug got approved by European Commission in February 2013 to treat the patients having severe manic episodes in bipolar I disorder Additionally, it got approval in Japan in January 2006 and in Canada in 2014.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Pharmacology:<\/jats:title>\n                    <jats:p>Aripiprazole shows high specificity for dopamine receptor especially D2 and D3, serotonin 5-HT1A and serotonin 5-HT2A receptors, reasonable specificity for dopamine D4, serotonin 5- HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors. It also shows moderate specificity for the serotonin reuptake. The major side effects include headache, agitation, akithesia, anxiety, tachycardia, insomnia, postural hypotension, constipation, vomiting, dizziness, nervousness and somnolence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The present article embarks the available information on Aripiprazole with emphasis on its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism and clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570163815666181008151718","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T07:33:29Z","timestamp":1539243209000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Aripiprazole: An FDA Approved Bioactive Compound to Treat Schizophrenia- A Mini Review"],"prefix":"10.2174","volume":"17","author":[{"given":"Arvind","family":"Kumar","sequence":"first","affiliation":[{"name":"Central Facility of Instrumentation, School of Pharmaceutical Sciences, IFTM University, Moradabad-244001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Singh","sequence":"additional","affiliation":[{"name":"Central Facility of Instrumentation, School of Pharmaceutical Sciences, IFTM University, Moradabad-244001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Mishra","sequence":"additional","affiliation":[{"name":"Central Facility of Instrumentation, School of Pharmaceutical Sciences, IFTM University, Moradabad-244001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Mishra","sequence":"additional","affiliation":[{"name":"Central Facility of Instrumentation, School of Pharmaceutical Sciences, IFTM University, Moradabad-244001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"277","volume":"151","author":"Krivoy A.","year":"2012","unstructured":"Krivoy A.; Fischel T.; Weizman A.; [The cognitive deficit in schizophrenia]. Harefuah 2012,151(5),277-280, 319","journal-title":"Harefuah"},{"key":"ref=2","first-page":"638","volume":"39","author":"Patel K.R.","year":"2014","unstructured":"Patel K.R.; Cherian J.; Gohil K.; Atkinson D.; Schizophrenia: overview and treatment options. P 2014,39(9),638-645","journal-title":"P"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0896-6273(00)00111-2","volume":"28","author":"Lewis D.A.","year":"2000","unstructured":"Lewis D.A.; Lieberman J.A.; Catching up on schizophrenia: natural history and neurobiology. Neuron 2000,28(2),325-334","journal-title":"Neuron"},{"key":"ref=4","first-page":"297","year":"2000","unstructured":"Diagnostic and Statistical Manual of Mental Disorders 2000,297-343","journal-title":"Diagnostic and Statistical Manual of Mental Disorders"},{"key":"ref=5","first-page":"1821","volume":"75","author":"Schultz S.H.","year":"2007","unstructured":"Schultz S.H.; North S.W.; Shields C.G.; Schizophrenia: a review. Am Fam Physician 2007,75(12),1821-1829","journal-title":"Am Fam Physician"},{"key":"ref=6","first-page":"167","volume":"31","author":"Macht D.L.","year":"1920","unstructured":"Macht D.L.; Contributions to psychopharmacology. Johns Hopkins Hosp Bullet 1920,31,167-173","journal-title":"Johns Hopkins Hosp Bullet"},{"key":"ref=7","first-page":"206","volume":"60","author":"Laborit H.","year":"1952","unstructured":"Laborit H.; Huguenard P.; Alluaume R.; Un nouveau stabilisateur v\u00e9g\u00e9tatif; le 4560 RP. Presse Med 1952,60(10),206-208","journal-title":"Presse Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1176\/ps.48.9.1137","volume":"48","author":"Meyer J.M.","year":"1997","unstructured":"Meyer J.M.; Simpson G.M.; From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiatr Serv 1997,48(9),1137-1139","journal-title":"Psychiatr Serv"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1056\/NEJM199103143241107","volume":"324","author":"Baldessarini R.J.","year":"1991","unstructured":"Baldessarini R.J.; Frankenburg F.R.; Clozapine. A novel antipsychotic agent. N Engl J Med 1991,324(11),746-754","journal-title":"N Engl J Med"},{"key":"ref=10","author":"Wang B","unstructured":"Wang B; Franklin JM; Eddings W; Landon J; Kesselheim AS.; Did FDA; Decisionmaking affect anti-psychotic drug prescribing in children?: A Time-Trend Analysis Plos 2016; 1-12."},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S1734-1140(11)70605-3","volume":"63","author":"Burda K.","year":"2011","unstructured":"Burda K.; Czubak A.; Kus K.; Nowakowska E.; Ratajczak P.; Zin J.; Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep 2011,63(4),898-907","journal-title":"Pharmacol Rep"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/jcp.0b013e3181618eb4","volume":"28","author":"Thase M.E.","year":"2008","unstructured":"Thase M.E.; Jonas A.; Khan A.; Bowden C.L.; Wu X.; McQuade R.D.; Carson W.H.; Marcus R.N.; Owen R.; Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008,28(1),13-20","journal-title":"J Clin Psychopharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1185\/03007995.2015.1123145","volume":"32","author":"Chue P.","year":"2016","unstructured":"Chue P.; Chue J.; A review of aripiprazole long-acting injection. Curr Med Res Opin 2016,32(3),441-452","journal-title":"Curr Med Res Opin"},{"key":"ref=14","first-page":"1","author":"Tanioka T.","year":"2012","unstructured":"Tanioka T.; Fuji S.; Kataoka M.; Retrospective study of japanese patients with schizophrenia treated with aripiprazole 2012,1-7","journal-title":"Retrospective study of japanese patients with schizophrenia treated with aripiprazole"},{"key":"ref=15","unstructured":"Health Canada Approves Otsuka and Lundbeck's Abilify Maintena\u00ae(Aripiprazole Once Monthly) as Treatment for Bipolar I Disorder in Adults. https:\/\/www.businesswire.com\/news\/ home\/20171102006599\/en\/Health-Canada-Approves-Otsuka-Lundbecks-Abilify-Maintena%C2%AE"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/jm940608g","volume":"41","author":"Oshiro Y.","year":"1998","unstructured":"Oshiro Y.; Sato S.; Kurahashi N.; Tanaka T.; Kikuchi T.; Tottori K.; Uwahodo Y.; Nishi T.; Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J Med Chem 1998,41(5),658-667","journal-title":"J Med Chem"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)10600-9","volume":"274","author":"Kikuchi T.","year":"1995","unstructured":"Kikuchi T.; Tottori K.; Uwahodo Y.; Hirose T.; Miwa T.; Oshiro Y.; Morita S.; 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995,274(1),329-336","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=18","first-page":"151","volume":"67","author":"Les A.","year":"2010","unstructured":"Les A.; Badowska-Roslonek K.; laszcz M, Duda AK, Baran P, Kaczmarek L. Optimization of aripiprazole synthesis. Acta Polon Pharma Drug Res 2010,67(2),151-157","journal-title":"Acta Polon Pharma Drug Res"},{"key":"ref=19","author":"Bingwen J","unstructured":"Bingwen J; Hui S; Zhengda Z.; Zhangjiagang Jiugu Technology Co, Ltd 2012; 1-7."},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","volume":"27","author":"Yokoi F.","year":"2002","unstructured":"Yokoi F.; Gr\u00fcnder G.; Biziere K.; Stephane M.; Dogan A.S.; Dannals R.F.; Ravert H.; Suri A.; Bramer S.; Wong D.F.; Dopamine D and D receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [C]raclopride. Neuropsychopharmacology 2002,27(2),248-259","journal-title":"Neuropsychopharmacology"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejmech.2012.11.042","volume":"60","author":"Zajdel P.","year":"2013","unstructured":"Zajdel P.; Marciniec K.; Ma\u015blankiewicz A.; Grychowska K.; Sata\u0142a G.; Duszy\u0144ska B.; Lenda T.; Siwek A.; Nowak G.; Partyka A.; Wr\u00f3bel D.; Jastrz\u0119bska-Wi\u0119sek M.; Bojarski A.J.; Weso\u0142owska A.; Paw\u0142owski M.; Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HTA\/5-HTA\/5-HT and dopamine D\/D receptors. Eur J Med Chem 2013,60,42-50","journal-title":"Eur J Med Chem"},{"key":"ref=22","first-page":"673","volume":"56","author":"Ge H.X.","year":"2006","unstructured":"Ge H.X.; Wang L.C.; Jiang Z.Z.; Ni S.L.; Synthesis and bioactivity of aripiprazole derivatives. Arzneimittelforschung 2006,56(10),673-677","journal-title":"Arzneimittelforschung"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00706-007-0782-3","volume":"139","author":"Avram S.","year":"2008","unstructured":"Avram S.; Berner H.; Milac A.L.; Wolschann P.; Quantitative structure \u2013 activity relationship studies on membrane receptors inhibition by antipsychotic drugs. Application to schizophrenia treatment. Monatsh Chem 2008,139,407-426","journal-title":"Monatsh Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","volume":"165","author":"Gr\u00fcnder G.","year":"2008","unstructured":"Gr\u00fcnder G.; Fellows C.; Janouschek H.; Veselinovic T.; Boy C.; Br\u00f6cheler A.; Kirschbaum K.M.; Hellmann S.; Spreckelmeyer K.M.; Hiemke C.; R\u00f6sch F.; Schaefer W.M.; Vernaleken I.; Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am J Psychiatry 2008,165(8),988-995","journal-title":"Am J Psychiatry"},{"key":"ref=25","year":"2006","unstructured":"Drug approval package, Abilify (aripiprazole) intramuscularinjectable solution. FDAU2006"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0924-977X(00)80351-X","volume":"10","author":"Mallikaarjun S.","year":"2000","unstructured":"Mallikaarjun S.; Salazar D.E.; Bramer S.L.; Pharmacokinetics, tolerability and safety of aripiprazole following single and multiple oral dose administration. Eur Neuropsychopharmacol 2000,10(Suppl. 3),306-307","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=27","unstructured":"FDA U. Inventor drug approval package, Abilify (aripiprazole) tablets."},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","volume":"16","author":"McGavin J.K.","year":"2002","unstructured":"McGavin J.K.; Goa K.L.; Aripiprazole. CNS Drugs 2002,16(11),779-786","journal-title":"CNS Drugs"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2133\/dmpk.22.358","volume":"22","author":"Kubo M.","year":"2007","unstructured":"Kubo M.; Koue T.; Maune H.; Fukuda T.; Azuma J.; Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007,22(5),358-366","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"S288","DOI":"10.1016\/S0924-977X(02)80404-7","volume":"12","author":"Carson W.","year":"2002","unstructured":"Carson W.; McQuade R.; Saha A.; Torbeyns A.; Stock E.; Aripiprazole versus placebo for re-lapse prevention in patients with chronic schizophrenia. Eur Neuropsychopharmacol 2002,12,S288-S8","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"Potkin S.G.","year":"2003","unstructured":"Potkin S.G.; Saha A.R.; Kujawa M.J.; Carson W.H.; Ali M.; Stock E.; Stringfellow J.; Ingenito G.; Marder S.R.; Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003,60(7),681-690","journal-title":"Arch Gen Psychiatry"},{"key":"ref=32","unstructured":"ABILIFY"},{"key":"ref=33","first-page":"S187","volume":"5","author":"Citrome L.","year":"2002","unstructured":"Citrome L.; Josiassen R.; Bark N.; Brown K.S.; Mallikaarjun S.; Salazar D.E.; Pharmacocinetics and safety of aripiprazole and concomitant mood stabilizers. Int J Neuropsychopharmacol 2002,5(Suppl. I),S187-S192","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1592\/phco.24.2.212.33145","volume":"24","author":"Argo T.R.","year":"2004","unstructured":"Argo T.R.; Carnahan R.M.; Perry P.J.; Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004,24(2),212-228","journal-title":"Pharmacotherapy"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ijpharm.2017.05.052","volume":"533","author":"Jamr\u00f3z W.","year":"2017","unstructured":"Jamr\u00f3z W.; Kurek M.; \u0141yszczarz E.; Szafraniec J.; Knapik-Kowalczuk J.; Syrek K.; Paluch M.; Jachowicz R.; 3D printed orodispersible films with Aripiprazole. Int J Pharm 2017,533(2),413-420","journal-title":"Int J Pharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1016\/j.clinthera.2015.10.006","volume":"37","author":"Kim Y.","year":"2015","unstructured":"Kim Y.; Jeon J.Y.; Chung Y.C.; Kim M.G.; Pharmacokinetics of a new orally disintegrating tablet formulation of aripiprazole 15 mg administered without water in healthy middle-aged korean subjects. Clin Ther 2015,37(12),2772-2779","journal-title":"Clin Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"Kane J.M.","year":"2002","unstructured":"Kane J.M.; Carson W.H.; Saha A.R.; McQuade R.D.; Ingenito G.G.; Zimbroff D.L.; Ali M.W.; Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002,63(9),763-771","journal-title":"J Clin Psychiatry"},{"key":"ref=38","first-page":"2635","volume":"11","author":"Di S G.","year":"2015","unstructured":"Di S G.; Riva M.A.; Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat 2015,11,2635-2647","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jpba.2017.12.049","volume":"151","author":"Wojnicz A.","year":"2018","unstructured":"Wojnicz A.; Belmonte C.; Koller D.; Ruiz-Nu\u00f1o A.; Rom\u00e1n M.; Ochoa D.; Abad-Santos F.; Effective phospholipids removing microelution-solid phase extraction LC-MS\/MS method for simultaneous plasma quantification of aripiprazole and dehydro-aripiprazole: Application to human pharmacokinetic studies. J Pharm Biomed Anal 2018,151,116-125","journal-title":"J Pharm Biomed Anal"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ajp.2017.02.015","volume":"27","author":"Mohan T.","year":"2017","unstructured":"Mohan T.; Dolan S.; Mohan R.; Dawson J.; Aripiprazole and impulse-control disorders in high-risk patients. Asian J Psychiatr 2017,27,67-68","journal-title":"Asian J Psychiatr"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jad.2017.10.035","volume":"227","author":"Calabrese J.R.","year":"2018","unstructured":"Calabrese J.R.; Sanchez R.; Jin N.; Amatniek J.; Cox K.; Johnson B.; Perry P.; Hertel P.; Such P.; McQuade R.D.; Nyilas M.; Carson W.H.; Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. J Affect Disord 2018,227(227),649-656","journal-title":"J Affect Disord"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejphar.2017.07.032","volume":"813","author":"Gholampour H.","year":"2017","unstructured":"Gholampour H.; Moezi L.; Shafaroodi H.; Aripiprazole prevents renal ischemia\/reperfusion injury in rats, probably through nitric oxide involvement. Eur J Pharmacol 2017,813,17-23","journal-title":"Eur J Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2017.12.006","volume":"148","author":"Yoo S.","year":"2018","unstructured":"Yoo S.; Kim M.Y.; Cho J.Y.; Syk and Src-targeted anti-inflammatory activity of aripiprazole, an atypical antipsychotic. Biochem Pharmacol 2018,148,1-12","journal-title":"Biochem Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jpba.2015.09.004","volume":"117","author":"\u0141aszcz M.","year":"2016","unstructured":"\u0141aszcz M.; Witkowska A.; Studies of phase transitions in the aripiprazole solid dosage form. J Pharm Biomed Anal 2016,117,298-303","journal-title":"J Pharm Biomed Anal"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pbb.2017.04.001","volume":"156","author":"Freeman E.","year":"2017","unstructured":"Freeman E.; Lin J.; Chow S.; Davis C.; Li M.; Sex differences in aripiprazole sensitization from adolescence to adulthood. Pharmacol Biochem Behav 2017,156,39-47","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0924-9338(11)72962-5","volume":"26","author":"Masand S.","year":"2011","unstructured":"Masand S.; Sherwood R.; Aitchison K.J.; P03-88 - An increase in bone stability in an aripiprazole add-on or switching study. Eur Psychiatry 2011,26(1),1257","journal-title":"Eur Psychiatry"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/166049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:31:37Z","timestamp":1775244697000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/166049\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,4,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163815666181008151718","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}